Literature DB >> 18236117

Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy.

Melanie B Thomas1, James P O'Beirne, Junji Furuse, Anthony T C Chan, Ghassan Abou-Alfa, Philip Johnson.   

Abstract

Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. This review summarizes the results of prospective clinical trials of several categories of systemic therapy, with emphasis on the more promising results from recent trials of biologically targeted therapeutic agents in HCC.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18236117     DOI： 10.1245/s10434-007-9705-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


  47 in total

1.  Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

Authors:  Robert J Lewandowski; Mary F Mulcahy; Laura M Kulik; Ahsun Riaz; Robert K Ryu; Talia B Baker; Saad M Ibrahim; Michael I Abecassis; Frank H Miller; Kent T Sato; Seanthan Senthilnathan; Scott A Resnick; Edward Wang; Ramona Gupta; Richard Chen; Steven B Newman; Howard B Chrisman; Albert A Nemcek; Robert L Vogelzang; Reed A Omary; Al B Benson; Riad Salem
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

2.  Hepatocellular carcinoma: the place of new medical therapies.

Authors:  Markus Peck-Radosavljevic
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

3.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

4.  Current chemotherapies for advanced hepatocellular carcinoma.

Authors:  Kazuhiro Nouso
Journal:  Clin J Gastroenterol       Date:  2013-02-06

5.  Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma.

Authors:  Fangping Wang; Zhiming Wu
Journal:  Exp Ther Med       Date:  2018-04-23       Impact factor: 2.447

6.  Development of self-forming doxorubicin-loaded polymeric depots as an injectable drug delivery system for liver cancer chemotherapy.

Authors:  Pinunta Nittayacharn; Norased Nasongkla
Journal:  J Mater Sci Mater Med       Date:  2017-05-22       Impact factor: 3.896

7.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

8.  Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.

Authors:  Fadia T Shaya; Ian M Breunig; Brian Seal; C Daniel Mullins; Viktor V Chirikov; Nader Hanna
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

9.  miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.

Authors:  Suna Zhou; Wenguang Ye; Yanjun Zhang; Dequan Yu; Qiuju Shao; Jun Liang; Mingxin Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

10.  Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.

Authors:  Haiyu Li; Zhenggang Ren; Xiaonan Kang; Lan Zhang; Xuefei Li; Yan Wang; Tongchun Xue; Yuefang Shen; Yinkun Liu
Journal:  BMC Cancer       Date:  2009-10-16       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.